Nav: Home

Study finds not all women get appropriate care for cervical cancer

March 02, 2017

ANN ARBOR, Michigan -- Women with locally advanced cervical cancer whose treatment follows national guidelines for care have better survival, regardless of race, ethnicity or stage of cancer.

But fewer than three out of five women received guideline-based care. For black and Hispanic women, it's just over half, a new study finds. And that could help explain why cervical cancer outcomes tend to be worse for these women.

Researchers looked at records from 16,195 patients treated between 2004 and 2012 for locally advanced cervical cancer. Patient information was reported to the National Cancer Database, which represents 96 percent of the cervical cancer cases in the United States.

To determine whether patients received care in line with national guidelines, the team looked at who received radiation therapy. National Comprehensive Cancer Network guidelines recommend radiation along with chemotherapy for locally advanced cervical cancer.

Overall, 57 percent of patients received guideline-based care. But those rates varied based on race, from 58 percent in white women to 53 percent in black women and 51 percent in Hispanic women.

What might be most surprising is that a larger gap in guideline-based care was seen among patients treated at centers that saw a large volume of cervical cancer patients, compared to low-volume hospitals.

"It's a common misconception," says study author Shitanshu Uppal, MBBS, assistant professor of obstetrics and gynecology at Michigan Medicine. Research looking at surgical outcomes suggests high-volume centers help reduce disparities. But treatment recommendations don't necessarily improve with practice.

"It's clear that the more surgeries you do, the better you get. But the 'more is better' mantra may not apply to guideline-concordant care," he says. "These are facilities that know what to do and they're doing it. But they're not doing it consistently across all populations."

Over the time period, guideline-based care increased across all populations, but black and Hispanic patients still were less likely than white patients to receive care consistent with guidelines.

"Overall, it's better for everyone. We're closing the gap, but there's still a gap. Even in 2012, we see a 5 percentage-point gap in guideline-based therapy," Uppal says.

The study, published in Obstetrics & Gynecology, did not address reasons why patients might not have received guideline-based care. Cervical cancer tends to be diagnosed in younger women and more often in women facing socioeconomic issues. These factors could influence a patient's likelihood to finish treatment, Uppal suggests. Some patients may refuse certain treatments.

The researchers plan to interview individual patients to better understand the reasons for this disparity, and why there might be barriers to some patients getting treatment.

Not that care will ever be 100 percent aligned with guidelines - there are too many complicated factors for each individual patient. But Uppal expects rates around 75 percent would be a reasonable goal. That's comparable to other types of cancer.

"Understanding the 'why' behind our findings is important - not just for minority populations but for all. We can do better," Uppal says.
-end-
Additional authors: Christina Chapman, M.D.; Ryan J. Spencer, M.D.; Shruti Jolly, M.D.; Kate Maturen, M.D.; J. Alejandro Rauh-Hain, M.D.; Marcela G. delCarmen, M.D.; Laurel W. Rice, M.D.

Funding: None

Disclosure: None

Reference: Obstetrics & Gynecology, Vol. 129, No. 2, doi: 10.1097/AOG.0000000000001819

Resources: University of Michigan Comprehensive Cancer Center, http://www.mcancer.org Michigan Medicine Cancer AnswerLine, 800-865-1125 Michigan Health Lab, http://www.MichiganHealthLab.org

Michigan Medicine - University of Michigan

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".